Rationale and design of the 2 by 2 factorial design GnG-trial: a randomized phase-III study to compare two schedules of gemtuzumab ozogamicin as adjunct to intensive induction therapy and to compare double-blinded intensive postremission therapy with or without glasdegib in older patients with newly diagnosed AMLSonia Jaramillo, Richard F. Schlenk, Johannes Krisam et al.|Trials|2021Cited by 7
Prior Treatment with Alemtuzumab Interferes with T-Cell Engraftment After Allogeneic Stem Cell Transplantation in Patients with Chronic Lymphocytic Leukemia.Johannes Schetelig, Gerhard Ehninger, Karin Kolbe et al.|Blood|2009Cited by 2
DNMT3A mutations in exon 23 are associated with improved survival in AML patients treated with Azacytidine plus standard chemotherapyPetra Tschanter, Carsten Müller‐Tidow, Utz Krug et al.|Kölner Universitäts PublikationsServer (Universität zu Köln)|2015Cited by 0
P554: RESULTS OF A RANDOMIZED PLACEBO-CONTROLLED PHASE 2 STUDY OF HYPOMETHYLATING AGENTS WITH OR WITHOUT ELTROMBOPAG IN ELDERLY AML PATIENTS (DELTA)Katja Sockel, Uwe Platzbecker, Anke Mütherig et al.|HemaSphere|2023Cited by 0